Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to 22.66%.

  • Gyre Therapeutics' EBIT Margin rose 60500.0% to 22.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.22%, marking a year-over-year increase of 837000.0%. This contributed to the annual value of 15.28% for FY2024, which is 745400.0% up from last year.
  • As of Q3 2025, Gyre Therapeutics' EBIT Margin stood at 22.66%, which was up 60500.0% from 8.11% recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' EBIT Margin registered a high of 39.84% during Q3 2023, and its lowest value of 1851.51% during Q1 2022.
  • Moreover, its 5-year median value for EBIT Margin was 8.11% (2025), whereas its average is 426.11%.
  • As far as peak fluctuations go, Gyre Therapeutics' EBIT Margin crashed by -14985500bps in 2021, and later skyrocketed by 18782400bps in 2023.
  • Quarter analysis of 5 years shows Gyre Therapeutics' EBIT Margin stood at 832.5% in 2021, then soared by 97bps to 22.13% in 2022, then crashed by -1425bps to 337.53% in 2023, then skyrocketed by 101bps to 2.39% in 2024, then soared by 850bps to 22.66% in 2025.
  • Its EBIT Margin stands at 22.66% for Q3 2025, versus 8.11% for Q2 2025 and 10.3% for Q1 2025.